Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(36%)
Results Posted
60%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
6
55%
Ph phase_4
3
27%

Phase Distribution

0

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
6(66.7%)
Phase 4Post-market surveillance
3(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Recruiting4
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (66.7%)
Phase 43 (33.3%)

Trials by Status

withdrawn19%
completed545%
terminated19%
recruiting436%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_2

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
recruitingphase_2

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

NCT07165769
completedphase_2

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

NCT01781338
recruitingphase_2

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

NCT06793553
completedphase_4

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

NCT03644485
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07149857Phase 2

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Recruiting
NCT07165769Phase 2

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

Recruiting
NCT01781338Phase 2

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Completed
NCT06793553Phase 2

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Recruiting
NCT03644485Phase 4

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

Completed
NCT04926584

Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

Recruiting
NCT04849377Phase 2

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Withdrawn
NCT01950819Phase 4

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Completed
NCT00923845Phase 2

Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Completed
NCT01005316

Alloantibodies in Pediatric Heart Transplantation

Terminated
NCT00207363Phase 4

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11